Immediate Delivery Versus Expectant Monitoring for Hypertensive Disorders of Pregnancy Between 34 and 37 Weeks of Gestation (HYPITAT-II): An Open-Label, Randomised Controlled Trial

Kim Broekhuijsen*, Gert-Jan van Baaren, Maria G. van Pampus, Wessel Ganzevoort, J. Marko Sikkema, Mallory D. Woiski, Martijn A. Oudijk, Kitty W. M. Bloemenkamp, Hubertina C. J. Scheepers, Henk A. Bremer, Robbert J. P. Rijnders, Aren J. van Loon, Denise A. M. Perquin, Jan M. J. Sporken, Dimitri N. M. Papatsonis, Marloes E. van Huizen, Corla B. Vredevoogd, Jozien T. J. Brons, Mesrure Kaplan, Anton H. van KaamHenk Groen, Martina M. Porath, Paul P. van den Berg, Ben W. J. Mol, Maureen T. M. Franssen, Josje Langenveld, HYPITAT-II Study Grp

*Bijbehorende auteur voor dit werk

OnderzoeksoutputAcademicpeer review

Samenvatting

Patients with hypertensive disorders of pregnancy usually have the 2 treatment options, either immediate delivery or continuing the pregnancy. Although immediately delivery of the placenta is seen as the more definitive of the 2 treatments, it does carry the potentially higher risks of an earlier birth (preterm if

Originele taal-2English
Pagina's (van-tot)605-607
Aantal pagina's3
TijdschriftObstetrical & Gynecological Survey
Volume70
Nummer van het tijdschrift10
DOI's
StatusPublished - okt-2015

Citeer dit